CGTLive’s Weekly Rewind – October 28, 2022


Review top news and interview highlights from the week ending October 28, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Cystinosis Gene Therapy Trial in Full Swing

The trial is being conducted at the University of California – San Diego under the leadership of Stephanie Cherqui, PhD.

2. TJ Cradick, PhD, on A Potential Cure for HIV With EBT-101

The chief scientific officer of Excision BioTherapeutics discussed the phase 1/2 clinical trial of the CRISPR gene editing therapy.

3. PR001 Hopes to Address Underlying Mutations in Neuronopathic Type 2 Gaucher Disease

CGTLive highlights the PROVIDE trial of PR001 for Gaucher Awareness Month.

4. Aimee Donald, MBChB, PhD, on Assessing PR001 in Children With Type 2 Gaucher Disease

The pediatrician from Royal Manchester Children’s Hospital discussed progress with the PROVIDE trial of PR001.

5. JC Virus T-Cell Therapy to be Evaluated in Progressive Multifocal Leukoencephalopathy

The trial expects to enroll its first patient in the first half of 2023.

Related Videos
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
Pat Furlong, BSN, RN, on Future Areas of Research in DMD
Michael Kelly, PhD, on Continuing Progress in Muscular Dystrophy in 2024
Sharon Hesterlee, PhD, on Further Research Needs With Muscular Dystrophies
Thomas Crawford, MD, on Taking a Closer Look at Nusinersen Data
© 2023 MJH Life Sciences

All rights reserved.